Skip to content
value.today

Hemaquest Pharmaceuticals

🇺🇸 Seattle, Washington, USAPharmaceuticalsFounded 2007
Total raised
$171 M
8 rounds on record
Latest round
$65 M
Feb 2021
First round on record
Jan 2010
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hemaquest Pharmaceuticals
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$65 MNo. 8$50 to $250 million

Hemaquest Pharmaceuticals: Raise no. 8, Feb 2021

Investors in this round

26 investors had bought by the notice of Mar 10, 2021: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Chevallard · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • Gur Roshwalb · Director
  • Michael Huang · Director
  • Richard Ghalie · Director
  • Roger Pomerantz · Director
  • Samuel Murphy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Chevallard, Chief Financial Officer and Chief Operating Officer. Source: SEC Form D, newest notice filed Mar 10, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$40 MNo. 7$10 to $50 million

Hemaquest Pharmaceuticals: Raise no. 7, Nov 2020

Investors in this round

14 investors had bought by the notice of Dec 10, 2020: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Chevallard · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • Gur Roshwalb · Director
  • Michael Huang · Director
  • Richard Ghalie · Director
  • Roger Pomerantz · Director
  • Samuel Murphy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Chevallard, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 10, 2020. Read the notice at the SEC.

equitySEC
Oct 2019$17 MNo. 6$10 to $50 million

Hemaquest Pharmaceuticals: Raise no. 6, Oct 2019

Investors in this round

21 investors had bought by the notice of Nov 5, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $25 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Chevallard · Executive Officer
  • David Slack · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • Barry Simon · Director
  • James Woody · Director
  • Michael Huang · Director
  • Richard Ghalie · Director
  • Samuel Murphy · Director
  • Standish Fleming · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Chevallard, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 5, 2019. Read the notice at the SEC.

equitySEC
Jan 2019$6 MNo. 5$2 to $10 million

Hemaquest Pharmaceuticals: Raise no. 5, Jan 2019

Investors in this round

25 investors had bought by the notice of Feb 12, 2019: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Slack · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • Barry Simon · Director
  • James Woody · Director
  • Patrick Soon-Shiong · Director
  • Richard Ghalie · Director
  • Standish Fleming · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold was cancellation of indebtedness”

Signed by Ivor Royston, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 12, 2019. Read the notice at the SEC.

equitySEC
Nov 2018$11 MNo. 4$10 to $50 million

Hemaquest Pharmaceuticals: Raise no. 4, Nov 2018

Investors in this round

6 investors had bought by the notice of Feb 12, 2019: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Slack · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • Barry Simon · Director
  • James Woody · Director
  • Patrick Soon-Shiong · Director
  • Richard Ghalie · Director
  • Standish Fleming · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold includes $10,000,000.08 of new cash and $695,494.65 of cancellation of indebtedness”

Signed by Ivor Royston, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 12, 2019. Read the notice at the SEC.

equitySEC
Mar 2017$10 MNo. 3$2 to $10 million

Hemaquest Pharmaceuticals: Raise no. 3, Mar 2017

Investors in this round

9 investors had bought by the notice of Apr 5, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $27 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Slack · Executive Officer
  • Ivor Royston · Executive Officer, Director
  • James Woody · Director
  • Patrick Soon-Shiong · Director
  • Richard Ghalie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$8,799,999.02 in new money; $1,075,624.54 in conversion of promissory notes.”

Signed by David Slack, Chief Business Officer. Source: SEC Form D, newest notice filed Apr 5, 2017. Read the notice at the SEC.

equitySEC
Mar 2012$7 MNo. 2$2 to $10 million

Hemaquest Pharmaceuticals: Raise no. 2, Mar 2012

Investors in this round

10 investors had bought by the notice of Apr 4, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $16 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John P. Longenecker · Executive Officer, Director
  • Richard P. Ghalie · Executive Officer
  • Tamara P. Seymour · Executive Officer
  • Armen P. Shanafelt · Director
  • Fred P. Dotzler · Director
  • George P. Stamatoyannopoulos · Director
  • Ivor P. Royston · Director
  • James P. Woody · Director
  • Naheed P. Misfeldt · Director
  • Paul P. Goddard · Director
  • Wayne P. Roe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara A. Seymour, Cfo. Source: SEC Form D, newest notice filed Apr 4, 2012. Read the notice at the SEC.

equitySEC
Jan 2010$16 MNo. 1$10 to $50 million

Hemaquest Pharmaceuticals: Raise no. 1, Jan 2010

Investors in this round

12 investors had bought by the notice of Aug 2, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Handfelt · Executive Officer
  • Ronald Berenson · Executive Officer, Director, Promoter
  • Susan Perrine · Executive Officer
  • Armen Shanafelt · Director
  • Frederick Dotzler · Director
  • George Stamatoyannopoulos · Director
  • Ivor Royston · Director
  • James N. Woody · Director
  • Naheed Misfeldt · Director
  • Paul Goddard · Director
  • Wayne Roe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nancy P.A. Williams, Attorney-in-Fact. Source: SEC Form D and 1 amendment, newest notice filed Aug 2, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hemaquest Pharmaceuticals chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2021

That is all the official record says: Hemaquest Pharmaceuticals has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hemaquest Pharmaceuticals is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hemaquest Pharmaceuticals
NameRoleNamed in
Daniel ChevallardExecutive officerMar 2021
Ivor RoystonExecutive officerMar 2021
David SlackExecutive officerNov 2019
John P. LongeneckerExecutive officerApr 2012
Richard P. GhalieExecutive officerApr 2012
Tamara P. SeymourExecutive officerApr 2012
Mark HandfeltExecutive officerAug 2010
Ronald BerensonExecutive officerAug 2010
Susan PerrineExecutive officerAug 2010
Bryan DunnivantExecutive officerFeb 2010
Gur RoshwalbDirectorMar 2021
Ivor RoystonDirectorMar 2021
Michael HuangDirectorMar 2021
Richard GhalieDirectorMar 2021
Roger PomerantzDirectorMar 2021
Samuel MurphyDirectorMar 2021
Barry SimonDirectorNov 2019
James WoodyDirectorNov 2019
Standish FlemingDirectorNov 2019
Patrick Soon-ShiongDirectorFeb 2019
Armen P. ShanafeltDirectorApr 2012
Fred P. DotzlerDirectorApr 2012
George P. StamatoyannopoulosDirectorApr 2012
Ivor P. RoystonDirectorApr 2012
James P. WoodyDirectorApr 2012
John P. LongeneckerDirectorApr 2012
Naheed P. MisfeldtDirectorApr 2012
Paul P. GoddardDirectorApr 2012
Wayne P. RoeDirectorApr 2012
Armen ShanafeltDirectorAug 2010
Frederick DotzlerDirectorAug 2010
George StamatoyannopoulosDirectorAug 2010
James N. WoodyDirectorAug 2010
Naheed MisfeldtDirectorAug 2010
Paul GoddardDirectorAug 2010
Ronald BerensonDirectorAug 2010
Wayne RoeDirectorAug 2010
Bryan DunnivantDirectorFeb 2010
Ronald BerensonPromoterAug 2010